All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Nathan Fowler, MD Anderson Cancer Center, Houston, US, and Chan Cheah, Sir Charles Gairdner Hospital, Nedlands, AU, about the latest trials in malignant lymphomas.
They discussed the results of trials investigating the use of CHOP chemotherapy and lenalidomide in newly diagnosed large cell lymphoma, and how two trials using these regimens had differing outcomes.
Prof Cheah spoke of the differences of these trials, such as the varying dosage of lenalidomide, and the positive and negative results of the two studies.
Interpretation of R2-CHOP in large cell lymphoma
New chemotherapy-free approaches for the treatment of lymphoid malignancies
At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances in chemotherapy-free options in the field of...
Lymphoma Hub Satellite Symposium 2019 | Chemo-free approaches for the treatment of lymphoid malignancies - Professor Nathan Fowler
Professor Nathan Fowler, University of Texas MD Anderson Cancer Centre, Houston, US, presented the current state of...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox